ReviewAdvanced pharmaceutical bulletin2012
Lactose engineering for better performance in dry powder inhalers.
Review in Advanced pharmaceutical bulletin, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 51 citations in OpenAlex.
- A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose.Pharmaceutical research · 2022Trial
- Advanced Pulmonary Drug Delivery Systems: A Narrative Review.Pulmonary therapy · 2026Review
- Continuous Electrospraying of Inhalable Biological Drug Products: Novel Formulation and Manufacturing Technology.Pharmaceutical research · 2026Article
- Development of Proniosomal Dry Powder for Dual Pulmonary Delivery of Salbutamol Sulfate and Carvacrol: A Design of Experiment Approach.Pharmaceutical research · 2026Article
- From Classics to Nano-Excipients and Biopolymers: Pulmonary Drug Delivery Formulations.Pharmaceutics · 2026Review
- Particle surface coating for dry powder inhaler formulations.Expert opinion on drug delivery · 2025Review
- Different Carriers for Use in Dry Powder Inhalers: Characteristics of Their Particles.Journal of aerosol medicine and pulmonary drug delivery · 2024Review
- Excipients for Novel Inhaled Dosage Forms: An Overview.AAPS PharmSciTech · 2024Review
- Complexities related to the amorphous content of lactose carriers.International journal of pharmaceutics: X · 2023Review
- Inhaled antibiotic-loaded polymeric nanoparticles for the management of lower respiratory tract infections.Nanoscale advances · 2021Review
- Novel Approaches for the Treatment of Pulmonary Tuberculosis.Pharmaceutics · 2020Review
- Dramatic improvement in dissolution rate of albendazole by a simple, one-step, industrially scalable technique.Research in pharmaceutical sciences · 2016Article
- Aggregated Nanotransfersomal Dry Powder Inhalation of Itraconazole for Pulmonary Drug Delivery.Advanced pharmaceutical bulletin · 2016Article
- Empirical modeling of the fine particle fraction for carrier-based pulmonary delivery formulations.International journal of nanomedicine · 2015Article
- Concept review of dry powder inhalers: correct interpretation of published data.Multidisciplinary respiratory medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry powder inhaler (DPI) is generally formulated as a powder mixture of coarse carrier particles and micronized drug with aerodynamic diameters of 1-5 μm. Carrier particles are used to improve drug particle flowability, thus improving dosing accuracy, minimizing the dose variability compared with drug alone and making them easier to handle during manufacturing operations. Lactose is the most common and frequently used carrier in DPIs formulations and nowadays various inhalation grades of lactose with different physico-chemical properties are available on the market. Therefore, the purpose of this manuscript is to review evolution of lactose as a carrier in inhalable formulations, their production and the impact of its physico-chemical properties on drug dispersion. This review offers a perspective on the current reported studies to modify lactose for better performance in DPIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.